menu
    • menu
    [{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Leukemia and Lymphoma Society | Therapeutics, Inc. | Veristat | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TetraLogic Pharmaceuticals \/ Leukemia and Lymphoma Society | Therapeutics, Inc. | Veristat | PPD","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Leukemia and Lymphoma Society | Therapeutics, Inc. | Veristat | PPD"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Dermatology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"},{"orgOrder":0,"company":"Medivir","sponsor":"Kavita Sarin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medivir \/ Kavita Sarin","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Kavita Sarin"},{"orgOrder":0,"company":"Medivir","sponsor":"Kavita Sarin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Kavita Sarin","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Kavita Sarin"}]

    Find Clinical Drug Pipeline Developments & Deals for Remetinostat

    Menu

    Remetinostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Medivir Strengthens the Business Development Potential of Remetinostat Through Renegotiated Multi-Party Agreem...

                            Details : The companies have restructured and streamlined the financial obligations for remetinostat, a topical histone deacetylase inhibitor, for the treatment of cutaneous T-cell lymphoma and other types of skin cancers.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous...

                            Details : The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2021

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kavita Sarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

                            Details : Remetinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Squamous Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2019

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kavita Sarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kavita Sarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

                            Details : Remetinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2017

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kavita Sarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

                            Details : SHP-141 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia Areata.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 21, 2015

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma

                            Details : SHP-141 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2014

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Leukemia and Lymphoma Society | Therapeutics, Inc. | Veristat | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphom...

                            Details : SHP-141 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2011

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Leukemia and Lymphoma Society | Therapeutics, Inc. | Veristat | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth